PerkinElmer And Invitrogen Enter Into Strategic Agreement To Streamline Drug Development
Collaboration Will Combine PerkinElmer's CellLux(TM) Live Cell Platform for Ion Channel Drug Discovery and Invitrogen's Voltage Sensor Probe Reagents
Boston & Carlsbad, CA - PerkinElmer, Inc. and Invitrogen Corporation announced a co-marketing partnership that will provide pharmaceutical and biotechnology companies with a powerful, integrated solution for high throughput cellular screening of ion channels, which are critical therapeutic targets implicated in many human physiological roles and for drug safety testing. This collaboration creates a rapid, highly reproducible and reliable platform for ion-channel drug discovery, replacing or improving previous studies which were limited to slow, non-robust and labor intensive methods.
Under the terms of the agreement, Invitrogen's Voltage Sensor Probes (VSP) ion channel reagents will be combined with PerkinElmer's CellLux Fluorescence Cellular Screening Platform. PerkinElmer is a global leader in health sciences and other advanced technology markets, and Invitrogen is an essential partner to companies in drug discovery, development and production.
CellLux is an automated cellular workstation specifically designed for cellular screening with sophisticated and highly sensitive ratiometric detection. It complements PerkinElmer's ViewLux ultraHTS Microplate Imager and the new LumiLux flash and glow Luminescence Cellular Screening Platform in lead discovery by enabling live cell kinetic ion channel screening. Invitrogen's Voltage Sensitive Probe reagents are ratiometric dyes that offer superior assay performance, accuracy and stability for even the most demanding ion channel applications. The ratiometric capabilities of both platforms combine to form a powerful solution for ion channel discovery and development programs. Additionally, the CellLux provides integrated liquid handling, data presentation and analysis software which contribute to its performance, utility and robustness.
"With the pharmaceutical industry's increased pressure to fill drug pipelines with more effective drug targets, this partnership will help our customers in transitioning to cellular screening, to drive fundamental productivity improvements into the drug discovery and development process," said Peter Coggins, PhD., president, PerkinElmer Life and Analytical Sciences. "This latest partnership is consistent with our strategy for expanding our cellular sciences portfolio, enabling drug companies to adopt more predictive and productive methodologies to increase their downstream success rates and allow drug candidates to get to the clinic sooner."
Invitrogen's drug discovery technologies have the ability to work on multiple instrument platforms, giving researchers the flexibility to meet their specific goals. By offering a wide variety of technologies, Invitrogen creatively combines product development and collaborative research to create research tools and custom solutions that accelerate the drug discovery process.
"The combination of PerkinElmer's versatile CellLux Platform and our VSP ion channel reagents has set a new standard for assay development and high throughput cellular screening that will allow drug makers to provide more effective drugs faster, without sacrificing quality or cost," said Nick Ecos, Vice President and General Manager of Invitrogen Corporation's Drug Discovery Solutions business. "We will continue to pair our technologies with those from industry-leading companies like PerkinElmer in order to capitalize on our integrated strength."
SOURCE: PerkinElmer, Inc.